2016 American Transplant Congress
Age Adapted Immunosuppression for Elderly Kidney Allograft Recipients: Balancing Risks for Cancer versus Rejection.
Introduction Cancer is a growing cause of morbidity and mortality after kidney transplantation, driven by immunosuppression. Age is one of the strongest risk factors for…2016 American Transplant Congress
Evaluation of T Cell Immunity in Elderly Solid Organ Transplant Recipients.
Elderly transplant recipients experience increased rates of death, especially death due to infection, as compared with younger patients. However, little is known about the mechanism…2016 American Transplant Congress
Patients with ESRD Due to Diabetes Have Higher Variability of Their Tacrolimus Levels and Worse Outcomes.
Imperial College Renal and Transplant Centre, Imperial College NHS Trust, London, United Kingdom.
IntroductionNonadherence to immunosuppressants is associated with rejection and graft loss and nonadherence to antidiabetics is associated with poor glycaemic control leading to microvascular complications and…2016 American Transplant Congress
Kinetics of Cytomegalovirus Load in Kidney Transplant Recipients Receiving Everolimus or Mycophenolate Sodium and No Pharmacological Prophylaxis.
Hospital do Rim, São Paulo, Brazil.
The purpose of this analysis is to investigate the kinetics of cytomegalovirus (CMV) viral load in kidney transplant recipients receiving tacrolimus (TAC) plus everolimus (EVR)…2016 American Transplant Congress
Initial Evaluation of Use of NAT in Assignment of CMV and EBV Infection Status in Children Awaiting Solid Organ Transplant.
Medicine, University of Alberta, Edmonton, Canada.
Purpose: The presence of passive antibodies, transfusion-acquired or maternal in infants, can make serologic determination of pre-transplant CMV and EBV status in children unreliable. We…2016 American Transplant Congress
An Evaluation of the Safety, Efficacy, and Pharmacoeconomics of Two Valganciclovir Prophylaxis Regimens Following Renal Transplantation.
1IU Health, University Hospital, Indianapolis, IN; 2Butler University, Indianapolis, IN.
Valganciclovir is the preferred prophylactic therapy for the prevention of CMV in transplant recipients and is the most expensive medication required post transplantation. The objective…2016 American Transplant Congress
Clinical Predictors of Progression and Clearance of Low Level CMV Viremia in Solid Organ Transplant Recipients.
Multi-Organ Transplant Program, University Health Network, Toronto, ON, Canada.
Background: Low level CMV viremia is common, and may either progress to higher viral loads that require therapy, or may spontaneously resolve. The clinical predictors…2016 American Transplant Congress
Polyfunctionality of CD8 T Cell Responses to Cytomegalovirus in Transplant Patients.
Background: Cytomegalovirus (CMV) infection causes significant morbidity including allograft damage in transplant patients. Primary infection with CMV is rapidly resolved in healthy individuals; memory T…2016 American Transplant Congress
Outcomes of Transplant Recipients Treated with Cidofovir for Resistant or Refractory Cytomegalovirus Infection.
Transplant & Oncology Infectious Disease, The Johns Hopkins University, Baltimore.
Background: Treatment of GCV-resistant(GCV-R)or refractory CMV infections in hematopoietic stem cell transplant (HSCT)and solid organ transplant (SOT)recipients remains controversial.Foscarnet (FOS)and cidofovir(CDV),nucleotide analogues with activity against…2016 American Transplant Congress
Cytomegalovirus Infection After Cardiac Transplantation.
University of British Columbia, Vancouver, Canada.
BackgroundOrthotopic heart transplantation (OHT) continues to be the gold standard for the management of patients with end-stage heart failure. However, complications following OHT may result…
American Transplant Congress abstracts